Gemifloxacin

May be taken with or without food.

Known hypersensitivity to gemifloxacin, other quinolones.

Patient w/ known or suspected CNS disorders (e.g. seizure disorders) or other risk factors predisposing to seizures, myasthenia gravis, previous tendon disorders (e.g. rheumatoid arthritis), history of QT interval prolongation, significant bradycardia or acute myocardial ischaemia, uncorrected electrolyte disorders. Kidney, heart or lung transplant recipients. Renal impairment. Pregnancy and lactation. Patient Counselling May impair ability to perform activities that require mental alertness or coordination (e.g. driving, operating machinery). Rest and refrain from doing strenuous physical activity as it may increase risk of tendon rupture. Avoid excessive exposure to sunlight or artificial UV light (e.g. tanning beds) and use protective measures (e.g. sunscreen, wear loose-fitting clothes) if staying outdoors is necessary during therapy. Monitoring Parameters Monitor WBC, signs and symptoms of infection and renal function.

Significant: Increased risk of mental health adverse effects (e.g. disturbance in attention, disorientation, agitation, nervousness, memory impairment, delirium); blood glucose disturbance and risk of coma with hypoglycaemia, prolonged QT interval, photosensitivity/phototoxicity, tendinitis, tendon rupture, peripheral neuropathy (may be irreversible). Blood and lymphatic system disorders: Leucopenia thrombocythemia. Cardiac disorders: Supraventricular tachycardia. Gastrointestinal disorders: Diarrhoea, nausea, vomiting, abdominal pain, constipation, flatulence, dyspepsia, dry mouth, gastritis. General disorders and administration site conditions: Fatigue. Infections and infestations: Fungal infection, genital moniliasis and pruritus, vaginitis. Metabolism and nutrition disorders: Anorexia, increased alkaline phosphatase, ALT, AST and creatine phosphokinase. Nervous system disorders: Seizures, increased intracranial pressure, nightmares, dizziness, tremors. Psychiatric disorders: Insomnia, anxiety, depression, toxic psychosis, paranoia, confusion, Skin and subcutaneous tissue disorders: Rash, urticaria, dermatitis. Vascular disorders: Syncope.
Potentially Fatal: Hypersensitivity reactions (e.g. anaphylaxis).

Additive effect on QT interval prolongation w/ class IA (e.g. quinidine) or class III (e.g. amiodarone) antiarrhythmics and other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Renal clearance reduced w/ probenecid. Decreased absorption w/ Al or Mg-containing antacids, buffered didanosine, sucralfate or dietary supplements containing metal cations (e.g. Zn, Mg, Fe). Increased risk of severe tendon disorders esp in elderly (>60 yr) w/ corticosteroids. May increase prothrombin time, INR and/or bleeding w/ warfarin.

Quinolones

J01MA15 - gemifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.